ODTX · Odyssey Therapeutics, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on ODTX. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About ODTX · Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Pre-revenue clinical-stage biotech with no near-term catalysts (>12 months to data), negligible open-market insider buying ($120k), and explicit anti-signals for dilution and low liquidity. Fails asymmetric thresholds.
Pre-revenue clinical-stage biotech with no near-term catalysts (>12 months to data), negligible open-market insider buying ($120k), and explicit anti-signals for dilution and low liquidity. Fails asymmetric thresholds.
Odyssey Therapeutics IPO'd at $18/share on May 7-8, 2026. The stock has already traded below its IPO price ($16.42 on day 1), presenting a potential discount to the institutional base cost. A genuine insider cluster is present: Jeffrey Leiden (board chair, former Vertex CEO) bought 5,000 shares at $20 on May 8 open-market — above the IPO price; CFO Jason Haas also bought 1,000 shares at $20 same day; and Dimension Capital director Nan Li purchased 1,111,111 shares in the offering itself. The Phase 2a topline data for lead asset OD-001 (RIPK2 inhibitor) was delivered April 2026 showing patient benefit across multiple endpoints with no serious adverse events — yet the stock trades below IPO price. This creates a potential misalignment between near-term clinical inflection and public market pricing.